Events

Rappel de ev3 NanoCross 0.14 OTW PTA Dilatation Catheter

Selon Valvira - National Supervisory Authority for Welfare and Health (via FOI), ce/cet/cette rappel concerne un dispositif en/au/aux/à Finland qui a été fabriqué par Ev3.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    2011-0079
  • Date
    2011-02-18
  • Pays de l'événement
    Finland
  • Source de l'événement
    VNSAWH
  • Notes / Alertes
    Finnish data is current through April 2018. All of the data comes from Valvira - National Supervisory Authority for Welfare and Health, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Finland.
  • Notes supplémentaires dans les données
    Source: NCAR
  • Cause
    Device failure / feature before use - design.

Device

ev3 NanoCross 0.14 OTW PTA Dilatation Catheter

Manufacturer

Ev3
  • Société-mère du fabricant (2017)
    Medtronic plc
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    VNSAWH